Maridebart Cafraglutide for sleep apnea in adults on CPAP
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a recent sleep test showing moderate to severe sleep apnea (AHI of 15 or higher).
- Your weight must be in the overweight or obese range (BMI 27 or higher).
- You need to have tried to lose weight before with diet and exercise, but not succeeded.
- You must be using a CPAP or similar breathing machine for sleep apnea, and have been using it for at least 3 months. You'll also need to keep using it during the trial.
- You cannot have had certain surgeries or have other major sleep or breathing conditions that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new weight-loss medication called maridebart cafraglutide against a placebo in people with moderate to severe obstructive sleep apnea who are not using a CPAP machine. The goal is to find out if weight loss can reduce symptoms like pauses in breathing during sleep.
This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.